Fennec Pharmaceuticals Inc stock sees notable price movement amidst recent company announcements.
Fennec Pharmaceuticals Inc (FRX.TO) has experienced a positive price action this week, closing at C$14.88 after a 7.44% increase in one day and a 6.67% rise over the week. This upward trend may be attributed to recent announcements regarding share offerings and financial performance.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$484.58M
52W high
$15.48
52W low
$7.59
1W change
+6.67%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 528.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+528.8% Upside
Current Price
C$14.88
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
52.2%
Annualized
90-Day Vol
82.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$17.79
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$15.79 | C$13.19 – C$18.91 |
| 60 trading days | C$16.76 | C$12.99 – C$21.62 |
| 90 trading days | C$17.79 | C$13.02 – C$24.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Fennec Pharmaceuticals has shown resilience in its stock performance, supported by recent financial results and share offerings. Investors should monitor the company's ongoing developments closely.
Fennec Pharmaceuticals reports a year-to-date stock increase of 42.94%.
The stock has demonstrated significant volatility, with a 52-week range of C$7.59 to C$15.48, indicating potential for both risk and reward.
Bull case
The company’s recent announcements point to strong growth, highlighted by record product sales and strategic financing efforts. These moves could enhance its position in the market.
Bear case
Despite the recent price gains, Fennec Pharmaceuticals is still operating at a loss, raising concerns about its long-term profitability and cash flow sustainability.
Recent Price Action
Advertisement
Fennec Pharmaceuticals Inc has reported a significant increase in its stock price this week, with a closing price of C$14.88. The stock has gained 7.44% in just one day and 6.67% over the week, reflecting a strong performance in the midst of ongoing developments.
Company News and Catalysts
While there are no major company news announcements this week, recent headlines indicate that Fennec Pharmaceuticals has been active in the capital markets. Notably, the company priced an underwritten public offering of common shares aiming to raise approximately $35 million. Additionally, they closed a private offering in Canada, further supporting their financial position. These actions suggest a proactive approach to funding and growth.
Technical Picture
The technical indicators for Fennec Pharmaceuticals show a 50-day moving average of C$13.93, which is 6.8% above the current price, and a 200-day moving average of C$11.41, indicating a 30.5% premium. The stock is currently trading in the upper range of its 52-week performance, which spans from C$7.59 to C$15.48. The stock's beta is 1.07, suggesting slightly higher volatility compared to the broader market. Volume has been low, with the latest trading volume at 101 shares, representing only 0.21 times the 20-day average volume of 474 shares.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
